US Colorectal Cancer Drug Pipeline Analysis

Publish Date:- Nov-2013       No Of Pages (242)

Electronic Access - Single User License $1500 Buy Now
CD-ROM Mail Delivery $1800Buy Now
Hard Copy Mail Delivery $1800 Buy Now
Electronic Access - Multi-User License $3000 Buy Now


Among all the regions affected with colorectal cancer, the US would continue to account for a giant’s share owing to its huge population base. With regards to rates of increase, it is most likely that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions of the disease. According to estimates, approximately 55,000 people die of this type of cancer in the US every year. In 2013, close to 142,820 people new cases are estimated to be diagnosed with colorectal cancer, including 102,480 case of colon cancer and 40,340 cases of rectal cancer.

US Colorectal Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Colorectal Cancer in US. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Colorectal Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Colorectal Cancer Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



US Colorectal Cancer Drug Pipeline by Clinical Phase:

• Research: 2

• Preclinical: 20

• Clinical: 2

• Phase-I: 16

• Phase-I/II: 12

• Phase-II: 42

• Phase-II/III: 2

• Phase-III: 7

• Marketed: 13


Among all the regions affected with colorectal cancer, the US would continue to account for a giant’s share owing to its huge population base. With regards to rates of increase, it is most likely that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions of the disease. According to estimates, approximately 55,000 people die of this type of cancer in the US every year. In 2013, close to 142,820 people new cases are estimated to be diagnosed with colorectal cancer, including 102,480 case of colon cancer and 40,340 cases of rectal cancer.

US Colorectal Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Colorectal Cancer in US. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Colorectal Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Colorectal Cancer Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



US Colorectal Cancer Drug Pipeline by Clinical Phase:

• Research: 2

• Preclinical: 20

• Clinical: 2

• Phase-I: 16

• Phase-I/II: 12

• Phase-II: 42

• Phase-II/III: 2

• Phase-III: 7

• Marketed: 13

1. US Colorectal Cancer Market Overview



2. Colorectal Cancer Drug Clinical Phase: Research

  2.1 Overview

  2.2 Colorectal Cancer Drug Profile in Clinical Phase



3. Colorectal Cancer Drug Clinical Phase: Preclinical

  3.1 Overview

  3.2 Colorectal Cancer Drug Profile in Clinical Phase



4. Colorectal Cancer Drug Clinical Phase: Clinical

  4.1 Overview

  4.2 Colorectal Cancer Drug Profile in Clinical Phase



5. Colorectal Cancer Drug Clinical Phase: Phase-I

  5.1 Overview

  5.2 Colorectal Cancer Drug Profile in Clinical Phase



6. Colorectal Cancer Drug Clinical Phase: Phase-I/II

  6.1 Overview

  6.2 Colorectal Cancer Drug Profile in Clinical Phase



7. Colorectal Cancer Drug Clinical Phase: Phase-II

  7.1 Overview

  7.2 Colorectal Cancer Drug Profile in Clinical Phase



8. Colorectal Cancer Drug Clinical Phase: Phase-II/III

  8.1 Overview

  8.2 Colorectal Cancer Drug Profile in Clinical Phase



9. Colorectal Cancer Drug Clinical Phase: Phase-III

  9.1 Overview

  9.2 Colorectal Cancer Drug Profile in Clinical Phase



10. Marketed

  10.1 Overview

  10.2 Marketed Colorectal Cancer Drug Profile


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name